Overview

A Phase 2, Double Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Participants

Status:
Not yet recruiting

Trial end date:
2027-11-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and effectiveness of treatment with once daily (QD) oral administration of dexlansoprazole 30 or 60 mg for 8 to 12 weeks in pediatric subjects aged 1 to 11 years inclusive, with erosive esophagitis (EE) and to assess the safety and effectiveness of dexlansoprazole 15 or 30 mg compared to placebo in maintenance of healed EE for 16 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole